Increased Mortality With Oral Platelet Glycoprotein IIb/IIIa Antagonists
نویسندگان
چکیده
منابع مشابه
Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials.
BACKGROUND Numerous clinical trials have established the benefits of intravenous glycoprotein IIb/IIIa inhibition in the management of coronary artery disease. In contrast, the recent large-scale, placebo-controlled, randomized trials of the oral glycoprotein IIb/IIIa antagonists have failed to provide commensurate reductions in late composite ischemic end points despite potent inhibition of pl...
متن کاملOral platelet glycoprotein IIb/IIIa receptor antagonists: the present challenge is safety.
An indisputable body of angiographic, angioscopic, pathological, and biochemical evidence supports the role of thrombus in the pathogenesis of acute myocardial infarction, unstable angina, and percutaneous coronary intervention. Compelling data from large-scale trials and analyses have established the role of platelet inhibitors in reducing coronary events in patients with the acute coronary sy...
متن کاملPlatelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease.
CONTEXT Thrombus formation on disrupted atherosclerotic plaque is the major cause of acute coronary events. Platelet inhibitors are the mainstay of drug therapy to reduce cardiac events in patients with acute coronary syndromes. The platelet glycoprotein (GP) IIb/IIIa receptor is the final common pathway of platelet aggregation. OBJECTIVES To review mechanisms of platelet activation and aggre...
متن کاملPlatelet glycoprotein IIb/IIIa antagonists: pharmacology and clinical developments.
PLATELETS are critical for normal hemostasis and thrombus formation. Thrombus formation initiated by platelets plays a central role in the pathogenesis of acute coronary syndromes (unstable angina and myocardial infarction). Platelets are involved in events causing angioplasty failure and stent thrombosis and may also play an important role in restenosis through the release of potent prothrombo...
متن کاملMedical decision making with incomplete evidence--choosing a platelet glycoprotein IIbIIIa receptor inhibitor for percutaneous coronary interventions.
BACKGROUND Medical decision making must often be performed despite incomplete evidence. An example is the choice of a glycoprotein IIb/IIIa (GP2b3a) inhibitor, a class of potent antiplatelet medications, as adjunctive therapy during percutaneous coronary interventions (PCIs). GP2b3a inhibitor efficacy in reducing adverse outcomes has been well documented with multiple placebo-controlled randomi...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Circulation
سال: 2001
ISSN: 0009-7322,1524-4539
DOI: 10.1161/01.cir.103.2.201